Liposomal amphotericin b for treatment of leishmaniasis: from the identification of critical physicochemical attributes to the design of effective topical and oral formulations

Página do item simplificado
dc.creatorFrédéric Jean Georges Frézard
dc.creatorMarta Marques Gontijo de Aguiar
dc.creatorLucas Antonio Miranda Ferreira
dc.creatorGuilherme Santos Ramos
dc.creatorThais Tunes Santos
dc.creatorGabriel Silva Marques Borges
dc.creatorVirgínia Mendes Russo Vallejos
dc.creatorHelane Lúcia Oliveira de Morais
dc.date.accessioned2025-07-14T17:32:46Z
dc.date.accessioned2025-09-09T01:23:44Z
dc.date.available2025-07-14T17:32:46Z
dc.date.issued2023-12
dc.format.mimetypepdf
dc.identifier.doi10.3390/pharmaceutics15010099
dc.identifier.issn19994923
dc.identifier.urihttps://hdl.handle.net/1843/83552
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofPharmaceutics
dc.rightsAcesso Aberto
dc.subjectLipossomos
dc.subjectAnfotericina B
dc.subjectAnfotericina B
dc.subjectLeishmaniose
dc.subjectVias de administração de medicamentos
dc.subject.otherliposomes
dc.subject.otherAmphotericin B
dc.subject.otherLeishmaniasis
dc.subject.otherOral route
dc.subject.otherPEGylation
dc.subject.otherTopical route
dc.titleLiposomal amphotericin b for treatment of leishmaniasis: from the identification of critical physicochemical attributes to the design of effective topical and oral formulations
dc.typeArtigo de periódico
local.citation.epage24
local.citation.issue1
local.citation.spage1
local.citation.volume15
local.description.resumoThe liposomal amphotericin B (AmB) formulation, AmBisome®, still represents the best therapeutic option for cutaneous and visceral leishmaniasis. However, its clinical efficacy depends on the patient’s immunological status, the clinical manifestation and the endemic region. Moreover, the need for parenteral administration, its side effects and high cost significantly limit its use in developing countries. This review reports the progress achieved thus far toward the understanding of the mechanism responsible for the reduced toxicity of liposomal AmB formulations and the factors that influence their efficacy against leishmaniasis. It also presents the recent advances in the development of more effective liposomal AmB formulations, including topical and oral liposome formulations. The critical role of the AmB aggregation state and release rate in the reduction of drug toxicity and in the drug efficacy by non-invasive routes is emphasized. This paper is expected to guide future research and development of innovative liposomal formulations of AmB.
local.publisher.countryBrasil
local.publisher.departmentFAR - DEPARTAMENTO DE PRODUTOS FARMACÊUTICOS
local.publisher.departmentICB - DEPARTAMENTO DE FISIOLOGIA E BIOFÍSICA
local.publisher.initialsUFMG
local.url.externahttps://www.mdpi.com/1999-4923/15/1/99

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Liposomal Amphotericin B for Treatment of Leishmaniasis.pdf
Tamanho:
2.91 MB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG